iTeos Therapeutics (ITOS) announced the intention to wind down its operations as part of a comprehensive review of strategic alternatives aimed at maximizing shareholder value. Following a thorough assessment of the Company’s development pipeline, business prospects, and financial position, the Company’s Board of Directors intends to wind down clinical and operational activities and focus on leveraging the Company’s cash balance to deliver near-term value to shareholders, including any proceeds from the potential sale of the Company’s intellectual property and assets such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics price target lowered to $13 from $16 at Wells Fargo
- iTeos Therapeutics price target lowered to $12 from $16 at Piper Sandler
- Leerink downgrades iTeos Therapeutics after termination of TIGIT program
- iTeos Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- iTeos Therapeutics downgraded to Market Perform from Outperform at Leerink